Bosentan

Generic Name: Bosentan

Brand Names: Stayveer, Tracleer

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉N_₅O_₆S

CAS Number: 147536-97-8

Unique Ingredient Identifier: XUL93R30K2

Background: Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.

Indication: Used in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).

Associated Conditions: NYHA Functional Class II-IV Pulmonary arterial hypertension, Ocular Inflammation, Ocular bacterial infections

Associated Therapies: -

Clinical Trials

Safety and Efficacy Study of Bosentan in Progressive Pulmonary Sarcoidosis

Phase 2

Terminated

Conditions: Sarcoidosis
Pulmonary Hypertension

Interventions: Drug: bosentan
Drug: placebo

First Posted Date: 2009-06-23

Last Posted Date: 2016-09-15

Lead Sponsor: Daniel Doberer

Target Recruit Count: 32

Registration Number: NCT00926627

Locations: 🇦🇹
General Hospital Vienna, Vienna, Austria
🇦🇹
Wilhelminenspital Wien, Vienna, Austria

Early Therapy of Pulmonary Arterial Hypertension

Not Applicable

Completed

Conditions: Pulmonary Hypertension
Systemic Sclerosis

Interventions: Drug: Bosentan

First Posted Date: 2009-05-28

Last Posted Date: 2011-09-23

Lead Sponsor: Medical University of Graz

Target Recruit Count: 10

Registration Number: NCT00909337

Locations: 🇦🇹
Medical University of Graz, Pulmonology, Graz, Austria

A Study to Evaluate the Use of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease

Phase 3

Conditions: Hypertension, Pulmonary
Connective Tissue Disease

Interventions: Drug: bosentan

First Posted Date: 2009-03-18

Last Posted Date: 2009-03-18

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 10

Registration Number: NCT00864201

Locations: 🇨🇦
Victoria Medical Center, Hamilton, Ontario, Canada

Insulin Resistance in Pulmonary Arterial Hypertension

Phase 2

Terminated

Conditions: Hypertension, Pulmonary

Interventions: Drug: bosentan
Drug: Pioglitazone

First Posted Date: 2009-01-21

Last Posted Date: 2017-03-31

Lead Sponsor: Stanford University

Target Recruit Count: 2

Registration Number: NCT00825266

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Safety and Efficacy of Bosentan in Patients With Diastolic Heart Failure and Secondary Pulmonary Hypertension

Phase 3

Completed

Conditions: Heart Failure, Diastolic
Hypertension, Pulmonary

Interventions: Drug: bosentan
Drug: placebo

First Posted Date: 2009-01-12

Last Posted Date: 2014-06-30

Lead Sponsor: University Teaching Hospital Hall in Tirol

Target Recruit Count: 20

Registration Number: NCT00820352

Locations: 🇦🇹
Hospital Wels/Grieskirchen, Wels, Upper Austria, Austria
🇦🇹
Hospital Hohenems, Hohenems, Austria
🇦🇹
Hospital Mostviertel Waidhofen/Ybbs, Waidhofen, Lower Austria, Austria

and more 4 locations

Bosentan for Poorly Controlled Asthma

Phase 2

Terminated

Conditions: Asthma

Interventions: Drug: bosentan
Drug: placebo

First Posted Date: 2008-12-30

Last Posted Date: 2012-10-01

Lead Sponsor: UConn Health

Target Recruit Count: 11

Registration Number: NCT00815347

Locations: 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States

Preventive Effects of Bosentan on the Systemic Cardiovascular Consequence of Sleep Apnea

Phase 2

Completed

Conditions: Obstructive Sleep Apnea
Hypertension

Interventions: Drug: bosentan
Device: nasal continuous positive airway pressure (CPAP)

First Posted Date: 2008-10-23

Last Posted Date: 2014-05-21

Lead Sponsor: University Hospital, Grenoble

Target Recruit Count: 19

Registration Number: NCT00777985

Locations: 🇫🇷
CHU de Grenoble, Grenoble, France

Effects of Non-Specific Endothelin-A Receptor Blockade on Ocular Blood Flow in Patients With Glaucoma

Phase 1

Completed

Conditions: Glaucoma
Blood Flow Velocity

First Posted Date: 2008-06-19

Last Posted Date: 2008-06-19

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 28

Registration Number: NCT00701597

Locations: 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

Effects of Bosentan on Respiratory Mechanics

Phase 4

Terminated

Conditions: Pulmonary Hypertension

Interventions: Drug: Bosentan

First Posted Date: 2008-05-16

Last Posted Date: 2015-08-20

Lead Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Target Recruit Count: 4

Registration Number: NCT00679068

Locations: 🇮🇹
Respiratory Unit, Fondazione S.Maugeri, Pavia, PV, Italy

Bosentan Use in Patients With Diabetic Nephropathy

Phase 3

Terminated

Conditions: Type 2 Diabetes

Interventions: Drug: bosentan

First Posted Date: 2008-03-18

Last Posted Date: 2020-07-24

Lead Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Target Recruit Count: 1

Registration Number: NCT00638131

Locations: 🇨🇦
CHUM, Montreal, Quebec, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy